<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Frogoudaki,A.A.</style></author><author><style face="normal" font="default" size="100%">Pantelakis,I.</style></author><author><style face="normal" font="default" size="100%">Bistola,V.</style></author><author><style face="normal" font="default" size="100%">Kroupis, C.</style></author><author><style face="normal" font="default" size="100%">Birba, D</style></author><author><style face="normal" font="default" size="100%">Ikonomidis, I.</style></author><author><style face="normal" font="default" size="100%">Alexopoulos, D</style></author><author><style face="normal" font="default" size="100%">Filippatos,G.</style></author><author><style face="normal" font="default" size="100%">Parissis, J</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Global Longitudinal Strain of the Systemic Ventricle Is Correlated with Plasma Galectin-3 and Predicts Major Cardiovascular Events in Adult Patients with Congenital Heart Disease</style></title><secondary-title><style face="normal" font="default" size="100%">Medicina (Kaunas.)</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style  face="normal" font="default" size="100%">Blood</style></keyword><keyword><style  face="normal" font="default" size="100%">Blood Proteins</style></keyword><keyword><style  face="normal" font="default" size="100%">Cardiovascular Diseases</style></keyword><keyword><style  face="normal" font="default" size="100%">Complications</style></keyword><keyword><style  face="normal" font="default" size="100%">Etiology</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Galectins</style></keyword><keyword><style  face="normal" font="default" size="100%">Greece</style></keyword><keyword><style  face="normal" font="default" size="100%">Heart Defects,Congenital</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">pathology</style></keyword><keyword><style  face="normal" font="default" size="100%">Predictive Value of Tests</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2020/06/22/</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">PM:32580463</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">56</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Backround and Objective: We sought to assess in adult congenital heart disease (ACHD) patients the prognostic value of plasma galectin-3 (Gal-3) levels and systemic ventricular global longitudinal strain (SV GLS) as well as their association with NTproBNP and arrhythmogenesis. Materials and Methods: We studied 58 patients (26 men, mean age 37 +/- 16.8 years) with various congenital heart diseases. Patients underwent echocardiogram, 24 h ambulatory ECG monitoring, while NTproBNP and Gal-3 were measured. They were followed up (median of 790.5 days -IQR 350.3 days) and major cardiovascular events (MACE) were recorded. Results. Mean Gal-3 levels were 17.07 +/- 6.38 ng/m. Plasma Gal-3 was correlated with LogNTproBNP (r = 0.456, p = 0.001).Gal-3 levels associated with supraventricular tachycardia (SVT) (p &lt; 0.001) and ventricular tachycardia (VT) (p &lt; 0.001), but was not associated with MACE (HR 1.018, 95% CI 0.944-1.098, p = 0.641).Mean SVGLS in patients with systemic left ventricle was -15.91% +/- 4.09%, which was significantly lower compared to patients with systemic right ventricle and patients with single ventricle (-11.42% +/- 3.37% and -11.9% +/- 5.06%, respectively, p = 0.021).SV GLS correlated with plasma Gal-3 (r = 0.313, p = 0.027) and logNTproBNP (r = 0.479, p &lt; 0.001). SVGLS correlated with VT arrhythmias (p = 0.004). NTproBNP predicted MACE (AUC 0.750, p = 0.03). SVGLS also predicted MACE (AUC 0.745, p = 0.03. In multivariate analysis, SVGLS and logNTproBNP maintained their predictive value (p = 0.004 and p = 0.009, respectively) Conclusion: In ACHD patients, SV GLS was found to predict MACE independently from NTproBNP and correlated with VT. Gal-3 correlated with NTproBNP and SVGLS as well as SVT and VT, but has not been shown to bear significant prognostic potential</style></abstract><issue><style face="normal" font="default" size="100%">6</style></issue><notes><style face="normal" font="default" size="100%">IS - 1648-9144 (Electronic)IS - 1010-660X (Print)IS - 1010-660X (Linking)LA - engPT - Journal ArticleRN - 0 (Biomarkers)RN - 0 (Blood Proteins)RN - 0 (Galectins)RN - 0 (LGALS3 protein, human)SB - IM</style></notes><custom5><style face="normal" font="default" size="100%">PMC7353898</style></custom5></record></records></xml>